248 related articles for article (PubMed ID: 29336268)
1. Anaplastic Lymphoma Kinase in Glioblastoma: Detection/Diagnostic Methods and Therapeutic Options.
Kalamatianos T; Denekou D; Stranjalis G; Papadimitriou E
Recent Pat Anticancer Drug Discov; 2018; 13(2):209-223. PubMed ID: 29336268
[TBL] [Abstract][Full Text] [Related]
2. Anaplastic lymphoma kinase expression and gene alterations in glioblastoma: correlations with clinical outcome.
Karagkounis G; Stranjalis G; Argyrakos T; Pantelaion V; Mastoris K; Rontogianni D; Komaitis S; Kalamatianos T; Sakas D; Tiniakos D
J Clin Pathol; 2017 Jul; 70(7):593-599. PubMed ID: 27993946
[TBL] [Abstract][Full Text] [Related]
3. Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.
Solomon B; Wilner KD; Shaw AT
Clin Pharmacol Ther; 2014 Jan; 95(1):15-23. PubMed ID: 24091716
[TBL] [Abstract][Full Text] [Related]
4. Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review.
Mesaros EF; Ott GR; Dorsey BD
Expert Opin Ther Pat; 2014 Apr; 24(4):417-42. PubMed ID: 24476492
[TBL] [Abstract][Full Text] [Related]
5. Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.
Klempner SJ; Ou SH
Chin Clin Oncol; 2015 Jun; 4(2):20. PubMed ID: 26112806
[TBL] [Abstract][Full Text] [Related]
6. Anaplastic lymphoma kinase as a therapeutic target.
Kruczynski A; Delsol G; Laurent C; Brousset P; Lamant L
Expert Opin Ther Targets; 2012 Nov; 16(11):1127-38. PubMed ID: 22998583
[TBL] [Abstract][Full Text] [Related]
7. Delivery systems and molecular targets of mechanism-based therapies for GBM.
Phuphanich S; Brat DJ; Olson JJ
Expert Rev Neurother; 2004 Jul; 4(4):649-63. PubMed ID: 15853584
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of the anaplastic lymphoma kinase.
Mologni L
Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic strategies to target multiple kinases in glioblastoma.
Sathornsumetee S
Anticancer Agents Med Chem; 2011 Oct; 11(8):700-11. PubMed ID: 21707500
[TBL] [Abstract][Full Text] [Related]
10. Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma.
Wallace GC; Dixon-Mah YN; Vandergrift WA; Ray SK; Haar CP; Mittendorf AM; Patel SJ; Banik NL; Giglio P; Das A
Metab Brain Dis; 2013 Sep; 28(3):355-66. PubMed ID: 23543207
[TBL] [Abstract][Full Text] [Related]
11. Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth.
Powers C; Aigner A; Stoica GE; McDonnell K; Wellstein A
J Biol Chem; 2002 Apr; 277(16):14153-8. PubMed ID: 11809760
[TBL] [Abstract][Full Text] [Related]
12. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.
Roskoski R
Pharmacol Res; 2013 Feb; 68(1):68-94. PubMed ID: 23201355
[TBL] [Abstract][Full Text] [Related]
13. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
Karachaliou N; Santarpia M; Gonzalez Cao M; Teixido C; Sosa AE; Berenguer J; Rodriguez Capote A; Altavilla G; Rosell R
Expert Opin Investig Drugs; 2017 Jun; 26(6):713-722. PubMed ID: 28463570
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
Katayama R; Lovly CM; Shaw AT
Clin Cancer Res; 2015 May; 21(10):2227-35. PubMed ID: 25979929
[TBL] [Abstract][Full Text] [Related]
15. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
16. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
Toyokawa G; Seto T; Takenoyama M; Ichinose Y
Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831
[TBL] [Abstract][Full Text] [Related]
17. Atypical PKCι as target for glioblastoma therapy.
Lorimer IA
Curr Cancer Drug Targets; 2015; 15(2):136-44. PubMed ID: 25643257
[TBL] [Abstract][Full Text] [Related]
18. Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients.
Le Rhun E; Chamberlain MC; Zairi F; Delmaire C; Idbaih A; Renaud F; Maurage CA; Grégoire V
CNS Oncol; 2015; 4(6):381-6. PubMed ID: 26498130
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy for NSCLC: ALK inhibition.
Pearson R; Kolesar JM
J Oncol Pharm Pract; 2012 Jun; 18(2):271-4. PubMed ID: 21844131
[TBL] [Abstract][Full Text] [Related]
20. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers.
Roskoski R
Pharmacol Res; 2017 Mar; 117():343-356. PubMed ID: 28077299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
